These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 1827701

  • 1. Androstanediolglucuronide: a parameter for peripheral androgen activity before and during therapy with cyproterone acetate.
    Ponjee GA, de Rooy HA, Vader HL.
    Acta Endocrinol (Copenh); 1991 Apr; 124(4):411-6. PubMed ID: 1827701
    [Abstract] [Full Text] [Related]

  • 2. Is plasma 5 alpha-androstane 3 alpha, 17 beta-diol glucuronide a biochemical marker of hirsutism in women?
    Giagulli VA, Giorgino R, Vermeulen A.
    J Steroid Biochem Mol Biol; 1991 Jul; 39(1):55-61. PubMed ID: 1829956
    [Abstract] [Full Text] [Related]

  • 3. [The clinical value of 3 alpha-androstanediol-glucuronide in hirsute women].
    Joura EA, Sator MO, Geusau A, Zeisler H, Söregi G, Huber JC.
    Wien Klin Wochenschr; 1997 Dec 12; 109(23):919-21. PubMed ID: 9487606
    [Abstract] [Full Text] [Related]

  • 4. Serum androstanediol glucuronide concentrations in normal and hirsute women and patients with thyroid dysfunction.
    Scanlon MJ, Whorwood CB, Franks S, Reed MJ, James VH.
    Clin Endocrinol (Oxf); 1988 Nov 12; 29(5):529-38. PubMed ID: 3253032
    [Abstract] [Full Text] [Related]

  • 5. Androgen levels during cyproterone acetate and ethinyl oestradiol treatment of hirsutism.
    Rubens R.
    Clin Endocrinol (Oxf); 1984 Mar 12; 20(3):313-25. PubMed ID: 6233049
    [Abstract] [Full Text] [Related]

  • 6. The influence of combined cyproterone acetate-ethinyl oestradiol therapy on serum levels of dehydroepiandrosterone, androstenedione, and testosterone in hirsute women.
    Frölich M, Lachinsky N, Moolenaar AJ.
    Acta Endocrinol (Copenh); 1977 Feb 12; 84(2):333-42. PubMed ID: 138326
    [Abstract] [Full Text] [Related]

  • 7. Effects of an oral contraceptive containing cyproterone acetate (Diane-35) on the symptoms, hormone profile, and ovarian volume of hirsute women with polycystic ovarian syndrome.
    Prelević GM, Puzigaća Z, Balint-Perić LA.
    Ann N Y Acad Sci; 1993 May 28; 687():255-62. PubMed ID: 8323181
    [No Abstract] [Full Text] [Related]

  • 8. Normal and elevated 3 alpha-androstanediol glucuronide concentrations in women with various causes of hirsutism and its correlation with degree of hirsutism and androgen levels.
    Pang S, Wang M, Jeffries S, Riddick L, Clark A, Estrada E.
    J Clin Endocrinol Metab; 1992 Jul 28; 75(1):243-8. PubMed ID: 1535633
    [Abstract] [Full Text] [Related]

  • 9. [Differential use of cyproterone acetate in androgen manifestations in the female].
    Kaiser E.
    Arch Gynecol Obstet; 1989 Jul 28; 245(1-4):985-6. PubMed ID: 2529830
    [No Abstract] [Full Text] [Related]

  • 10. Comparison of four different treatment regimes in hirsutism related to polycystic ovary syndrome.
    Gökmen O, Senöz S, Gülekli B, Işik AZ.
    Gynecol Endocrinol; 1996 Aug 28; 10(4):249-55. PubMed ID: 8908525
    [Abstract] [Full Text] [Related]

  • 11. Antiandrogens and hirsutism.
    Biffignandi P, Molinatti GM.
    Horm Res; 1987 Aug 28; 28(2-4):242-9. PubMed ID: 2969862
    [Abstract] [Full Text] [Related]

  • 12. Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives.
    Mastorakos G, Koliopoulos C, Creatsas G.
    Fertil Steril; 2002 May 28; 77(5):919-27. PubMed ID: 12009344
    [Abstract] [Full Text] [Related]

  • 13. [Therapy of female hirsutism: current status and new findings].
    De Pedrini P, Suraci C, Costa C.
    Clin Ter; 1983 Mar 31; 104(6):447-55. PubMed ID: 6221859
    [No Abstract] [Full Text] [Related]

  • 14. [Hirsutism treated with cyproterone acetate and ethinyl estradiol. Influence on androgens in the serum and urine and on urinary cortisol].
    Nielsen DR, Larsen J, Pedersen IM, Starup J.
    Ugeskr Laeger; 1985 Aug 12; 147(33):2589-93. PubMed ID: 2933857
    [No Abstract] [Full Text] [Related]

  • 15. A new association of ethinylestradiol (0.035 mg) cyproterone acetate (2 mg) in the therapy of polycystic ovary syndrome.
    Falsetti L, Dordoni D, Gastaldi C, Gastaldi A.
    Acta Eur Fertil; 1986 Aug 12; 17(1):19-25. PubMed ID: 2941960
    [Abstract] [Full Text] [Related]

  • 16. [Cyproterone acetate. 15 cases of hirsutism treated for 1 year].
    Houdent C, Kuhn JM, Balacheff O, Leclerc P, Legrand A, Wolf LM.
    Ann Endocrinol (Paris); 1983 Aug 12; 44(6):397-401. PubMed ID: 6234850
    [Abstract] [Full Text] [Related]

  • 17. [Hirsutism].
    van Zuuren EJ, Pijl H.
    Ned Tijdschr Geneeskd; 2007 Oct 20; 151(42):2313-8. PubMed ID: 18064932
    [Abstract] [Full Text] [Related]

  • 18. Hair growth and androgen responses in hirsute women treated with continuous cyproterone acetate and cyclical ethinyl oestradiol.
    Jones DB, Ibraham I, Edwards CR.
    Acta Endocrinol (Copenh); 1987 Dec 20; 116(4):497-501. PubMed ID: 2962412
    [Abstract] [Full Text] [Related]

  • 19. Comparison of sequential cyproterone acetate/estrogen versus spironolactone/oral contraceptive in the treatment of hirsutism.
    O'Brien RC, Cooper ME, Murray RM, Seeman E, Thomas AK, Jerums G.
    J Clin Endocrinol Metab; 1991 May 20; 72(5):1008-13. PubMed ID: 1827125
    [Abstract] [Full Text] [Related]

  • 20. [Treatment of hyperandrogenism in women with cyproterone acetate].
    Julesz J, Faredin I, Tóth I, László F.
    Orv Hetil; 1981 May 17; 122(20):1177-80. PubMed ID: 6455637
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.